View Item 

Show simple item record

Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection
dc.contributor.authorTrachtman, Hen_US
dc.contributor.authorFrymoyer, Aen_US
dc.contributor.authorLewandowski, Aen_US
dc.contributor.authorGreenbaum, LAen_US
dc.contributor.authorFeig, DIen_US
dc.contributor.authorGipson, DSen_US
dc.contributor.authorWarady, BAen_US
dc.contributor.authorGoebel, JWen_US
dc.contributor.authorSchwartz, GJen_US
dc.contributor.authorLewis, Ken_US
dc.contributor.authorAnand, Ren_US
dc.contributor.authorPatel, UDen_US
dc.date.accessioned2015-07-01T20:56:28Z
dc.date.available2016-08-08T16:18:39Zen
dc.date.issued2015-07en_US
dc.identifier.citationTrachtman, H; Frymoyer, A; Lewandowski, A; Greenbaum, LA; Feig, DI; Gipson, DS; Warady, BA; Goebel, JW; Schwartz, GJ; Lewis, K; Anand, R; Patel, UD (2015). "Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection." Clinical Pharmacology & Therapeutics 98(1): 25-33.en_US
dc.identifier.issn0009-9236en_US
dc.identifier.issn1532-6535en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111964
dc.publisherWiley Periodicals, Inc.en_US
dc.titlePharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selectionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111964/1/cpt127.pdf
dc.identifier.doi10.1002/cpt.127en_US
dc.identifier.sourceClinical Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceRhodin, M.M. et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67 – 76 ( 2009 ).en_US
dc.identifier.citedreferenceCross, N.B., Webster, A.C., Masson, P., O'Connell, P.J. & Craig, J.C. Antihypertensives for kidney transplant recipients: systematic review and meta‐analysis of randomized controlled trials. Transplantation 88, 7 – 18 ( 2009 ).en_US
dc.identifier.citedreferenceNielsen, S.E. et al. Neutrophil gelatinase‐associated lipocalcin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross‐sectional study and the effects of lisinopril. Diabet. Med. 27, 1144 – 1150 ( 2010 ).en_US
dc.identifier.citedreferenceInigo, P. et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF‐β(1) plasma levels in a crossover trial in renal transplant recipients. J. Am. Soc. Nephrol. 12, 822 – 827 ( 2001 ).en_US
dc.identifier.citedreferenceHernandez, A.A. et al. Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain. NDT Plus 3 ( supp.l 2 ), ii21 – ii25 ( 2010 ).en_US
dc.identifier.citedreferenceSorof, J.M., Goldstein, S.L., Brewer, E.D., Steiger, H.M. & Portman, R.J. Use of anti‐hypertensive medications and posttransplant renal allograft function in children. Pediatr. Transplant 4, 21 – 27 ( 2000 ).en_US
dc.identifier.citedreferenceRemuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288 – 296 ( 2006 ).en_US
dc.identifier.citedreferenceKnutter, I. et al. Transport of angiotensin‐converting enzyme inhibitors by H+/peptide transporters revisited. J. Pharmacol. Exp. Therap. 327, 432 – 441 ( 2008 ).en_US
dc.identifier.citedreferenceHogg, R.J. et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr. Nephrol. 22, 695 – 701 ( 2007 ).en_US
dc.identifier.citedreferencePrinivil® (lisinopril tablets) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc., 2003.en_US
dc.identifier.citedreferenceQin, F., Wang, D., Yang, S., Jing, L., Xiong, Z. & Li, F. Quantitative determination of lisinopril in human plasma by high performance liquid chromatography‐tandem mass spectrometry and its application in a pharmacokinetic study. Biomed. Chromatogr. 26, 691 – 696 ( 2012 ).en_US
dc.identifier.citedreferenceLin, J.H., Chen, I.W., Ulm, E.H. & Duggan, D.E. Differential handling of angiotensin‐converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab. Dispos. 16, 392 – 396 ( 1988 ).en_US
dc.identifier.citedreferenceU.S. Food and Drug Administration Clinical Pharmacology and Biopharmaceutics Review. CDER Approval Package for Prinivil®: Application Number 19‐558/S‐043. 2003. < http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/19-558S043_Prinivil.cfm >. Accessed 22 July, 2014.en_US
dc.identifier.citedreferenceHeads of Medicines Agencies. Lisinopril Paediatric Public Assessment Report: SE/W/002/pdWS/001.” 2009. < http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Lisinopril_2009_11b_45PaedPAR.pdf >. Accessed 22 July, 2014.en_US
dc.identifier.citedreferenceAnderson, B.J. & Holford, N.H.G. Mechanism‐based concepts of size and maturity in pharmacokinetics. Ann. Rev. Pharmacol. Toxicol. 48, 303 – 332 ( 2008 ).en_US
dc.identifier.citedreferenceHolford, N., Heo, Y.A. & Anderson, B. A pharmacokinetic standard for babies and adults. J. Pharm. Sci. 102, 2941 – 2952 ( 2013 ).en_US
dc.identifier.citedreferenceZestril® (lisinopril tablets) [package insert]. Wilmington, DE: AstraZeneca, 2009.en_US
dc.identifier.citedreferencevan Schaik, B.A., Geyskes, G.G., van der Wouw, P.A., van Rooij, H.H. & Porsius, A.J. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Eur. J. Clin. Pharmacol. 34, 61 – 65 ( 1988 ).en_US
dc.identifier.citedreferenceSoffer, B., Zhang, Z., Miller, K., Vogt, B.A. & Shahinfar, S. A double‐blind, placebo‐controlled, dose‐response study of the effectiveness and safety of lisinopril for children with hypertension. Am. J. Hypertens. 16, 795 – 800 ( 2003 ).en_US
dc.identifier.citedreferenceHermida, R.C. et al. Chronotherapeutics of conventional blood pressure‐lowering medications: a simple, low‐cost means of improving management and treatment outcomes of hypertensive‐related disorders. Curr. Hypertens. Rep. 16, 412 ( 2014 ).en_US
dc.identifier.citedreferenceSiddique, K., Leonard, D., Borders, L. & Seikaly, M.G. Validation of the CkiD formulae to estimate GFR in children post renal transplant. Pediatr. Nephrol. 29, 445 – 451 ( 2014 ).en_US
dc.identifier.citedreferenceKnoll, G.A. et al. The Canadian ACE‐inhibitor trial to improve renal outcomes and patient survival in kidney transplantation—study design. Nephrol. Dial. Transplant 23, 354 – 335 ( 2008 ).en_US
dc.identifier.citedreferenceESCAPE Trial Group, et al. Strict blood‐pressure control and progression of renal failure in children. N. Engl. J. Med. 361, 1639 – 1650 ( 2009 ).en_US
dc.identifier.citedreferenceSchwartz, G.J. et al. New equations to estimate GFR in children. J. Am. Soc. Nephrol. 20, 629 – 637 ( 2009 ).en_US
dc.identifier.citedreferenceMitsnefes, M.M., Khoury, P.R. & McEnery, P.T. Early post‐transplantation hypertension and poor long‐term renal allograft survival in pediatric patients. J. Pediatr. 143, 98 – 103 ( 2003 ).en_US
dc.identifier.citedreferenceSilverstein, D.M., LeBlanc, P., Hempe, J.M., Ramcharan, T. & Boudreaux, J.P. Tracking of blood pressure and its impact on graft function in pediatric renal transplant recipients. J. Pediatr. Transplant 11, 860 – 867 ( 2007 ).en_US
dc.identifier.citedreferenceMitsnefes, M.M., Omoloja, A. & McEnery, P.T. Short‐term pediatric renal transplant survival: blood pressure and allograft function. Pediatr. Transplant 5, 160 – 165 ( 2001 ).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cpt127.pdf
Size:
294.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.